Regeneron Pharmaceuticals
REGN
Market cap $55.9B

529.24 USD

+7.40

1.42%

At close Jun 13, 4:00 PM EDT

After hours

528.02

-1.22

0.23%

1 day

1.42%

5 days

6.27%

1 month

-7.82%

3 months

-22.24%

6 months

-27.63%

Year to date

-26.00%

1 year

-48.44%

5 years

-10.38%

10 years

6.05%

About: Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Employees: 15,158

Healthcare Biotechnology

0

Funds holding %

of 7,296 funds

0

Analysts bullish %

of 15 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

14% more repeat investments, than reductions

Existing positions increased: 510 | Existing positions reduced: 446

7% more funds holding in top 10

Funds holding in top 10: 14 [Q4 2024] → 15 (+1) [Q1 2025]

3% less call options, than puts

Call options by funds: $974M | Put options by funds: $1B

7% less first-time investments, than exits

New positions opened: 137 | Existing positions closed: 147

1.21% less ownership

Funds ownership: 86.11% [Q4 2024] → 84.9% (-1.21%) [Q1 2025]

3% less funds holding

Funds holding: 1,296 [Q4 2024] → 1,260 (-36) [Q1 2025]

13% less capital invested

Capital invested by funds: $66.3B [Q4 2024] → $57.8B (-$8.48B) [Q1 2025]

See Fund Rankings

Research analyst outlook

15 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$547

3%

upside

Avg. target

$735

39%

upside

High target

$943

78%

upside

15 analyst ratings

11 positive

73%

3 neutral

20%

1 negative

7%

JP Morgan Chris Schott	51%upside $800	Overweight Maintained	9 Jun 2025
UBS Trung Huynh	6%upside $560	Neutral Maintained	5 Jun 2025
Citigroup Geoff Meacham	23%upside $650	Buy Maintained	2 Jun 2025
BMO Capital Evan David Seigerman	13%upside $600	Outperform Maintained	2 Jun 2025
Morgan Stanley Matthew Harrison	43%upside $755	Overweight Maintained	2 Jun 2025

See Analyst Rankings

Financial journalist opinion

Based on 53 articles about REGN published over the past 30 days

The Motley Fool

These Were the 2 Worst-Performing Stocks in the Nasdaq-100 in May 2025

The Nasdaq-100 market index holds a lot of volatile stocks. Some of its top performers seem overvalued today, while others seem to have room for further growth.

These Were the 2 Worst-Performing Stocks in the Nasdaq-100 in May 2025

The Motley Fool

Is This Stock a Buy After Acquiring a Potential Zepbound Competitor?

Shares of Regeneron (REGN 0.44%) have declined this year due to issues with one of its former growth drivers, Eylea, a medicine that treats wet age-related macular degeneration. The therapy is facing stiff competition, biosimilar and otherwise, that is eating into its market share.

Is This Stock a Buy After Acquiring a Potential Zepbound Competitor?

CNBC Television

Regeneron CEO on 23andMe bid: Trying to balance individual privacy with biotech & genetics research

Regeneron founder, chairman and CEO Dr. Leonard Schleifer joins 'Squawk Box' to discuss the company's bid for 23andMe, privacy concerns over 23andMe's genetic data, importance of biotechnology, and more.

Regeneron CEO on 23andMe bid: Trying to balance individual privacy with biotech & genetics research

Regeneron Pharma Shares Rise Over 3% After Key Signal

REGN climbs over 16 points after the alert

Regeneron Pharma Shares Rise Over 3% After Key Signal

Regeneron Pharmaceuticals, Inc. (REGN) Presents at 46th Annual Goldman Sachs Global Healthcare Conference Transcript

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) 46th Annual Goldman Sachs Global Healthcare Conference June 9, 2025 10:40 AM ET Company Participants Christopher R. Fenimore - Executive VP of Finance & CFO Ryan Crowe - Senior Vice President of Investor Relations & Strategic Analysis Conference Call Participants Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division Salveen Jaswal Richter Great.

Regeneron Pharmaceuticals, Inc. (REGN) Presents at 46th Annual Goldman Sachs Global Healthcare Conference Transcript

Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color

Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75% or greater improvement in overall disease severity, the primary endpoint, in more than three-quarters of treated patients Patients experienced substantial reductions in hyperpigmentation, dry skin and itch from baseline Results support commitment to enhance clinical understanding of chronic diseases in communities of color TARRYTOWN, N.Y. and PARIS, June 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented results from the DISCOVER Phase 4, single-arm, open-label trial assessing Dupixent® (dupilumab) in adults and adolescents with moderate-to-severe atopic dermatitis with skin of color.

Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color

Investors Business Daily

The New Twist In Regeneron's 23andMe Bankruptcy Buyout

23andMe wants to reopen bidding on its assets after former CEO Anne Wojcicki put together a $305 million offer, topping Regeneron.

The New Twist In Regeneron's 23andMe Bankruptcy Buyout

Zacks Investment Research

REGN Strengthens Obesity Pipeline: Will the Move Revive the Stock?

REGN inks a $2B-plus obesity drug deal with Hansoh, aiming to expand its pipeline amid slumping Eylea sales and pipeline setbacks.

REGN Strengthens Obesity Pipeline: Will the Move Revive the Stock?

Why Regeneron Is Falling And Why You Should Avoid It

Regeneron Pharmaceuticals (REGN) has been in a persistent downtrend for over 280 days. The stock is currently in the 10th Phase of its 18-Phase Adhishthana Cycle, our proprietary cyclical framework.

Why Regeneron Is Falling And Why You Should Avoid It

REGN Stock Undervalued At $500?

Regeneron Pharmaceuticals (NASDAQ:REGN) shares witnessed a notable 19% decline on Friday, May 30, in the wake of the unexpected failure of itepekimab, its chronic obstructive pulmonary disease (COPD) treatment in conjunction with Sanofi, during a late-stage clinical trial. One of the two trials did not achieve its primary endpoint, which is a significant setback considering that itepekimab was anticipated to become a blockbuster drug, with peak sales projections from Sanofi estimated between $2 billion and $6 billion.

REGN Stock Undervalued At $500?

See News Rankings

Charts implemented using Lightweight Charts™